(Sharecast News) - Crism Therapeutics said on Monday that it has received both regulatory clearance from the UK Medicines and Healthcare products Regulatory Agency (MHRA) and ethical approval from a UK Research Ethics Committee to begin its registration-grade phase two trial of irinotecan-ChemoSeed in glioblastoma patients.
The AIM-traded firm said the...

Email this article to a friend

or share it with one of these popular networks:

• DIGG
• FACEBOOK
• STUMBLEUPON
• MIXX
• YAHOO BUZZ
• DELICIOUS
• REDDIT
• NEWSVINE